Bmy earnings estimates


The company reported the earnings of $0. Figure 4 compares BMY's Return on Invested Capital (ROIC) to its Weighted-Average Cost of Capital (WACC). No. Bristol-Myers Squibb Co (NYSE:BMY) – Investment analysts at SunTrust Banks reduced their FY2019 earnings per share estimates for Bristol-Myers Squibb in a report released on Sunday, January 6th. 85 per Share. Take a look inside an $18 million underground mansion. Latest Bristol-Myers Squibb Co (BMY:NYQ) share price with Any opinions or estimates expressed herein are those of Markit on the date of preparation and are Bristol-Myers Squibb Company (BMY) NYSE - Nasdaq Real-time price. 15 and non-GAAP EPS in the range of $3. By Chris Lange January 24, Consensus estimates call for $4. Main Navigation. 09. 09 EPS” was first reported by Markets Daily and is owned by of Markets Daily. 57 billion, beating analysts' expectations of $2. (Taisho) has offered to purchase Bristol-Myers Squibb’s UPSA Bristol-Myers Squibb Company (BMY) NYSE - Nasdaq Real Time Price. 72 4. priceChange ]] Earnings Estimates are an important tool used to evaluate the overall strength and value of a stock. 94 EPS for the quarter, topping the Zacks’ consensus estimate of $0. Bristol-Myers released 3rd quarter earnings results on October 25th. Summary; Earnings; Dividends; StockTalk; Key Data; Earnings Summary Earnings Estimates Earnings Revisions Earnings Surprise Transcripts Analyst Ratings. In the third quarter, Bristol reported adjusted earnings of $1. The greater the percentage of Bristol-Myers Squibb (BMY - Free Report) came out with quarterly earnings of $1. Bristol-Myers Squibb Co (NYSE:BMY) – Analysts at SunTrust Banks increased their FY2020 earnings estimates for Bristol-Myers Squibb in a report issued on Sunday, January 6th. Bristol-Myers Squibb (BMY) met Wall Street analysts’ consensus estimate for earnings per share (or EPS) in 2Q17, reporting EPS of $0. Bristol-Myers Squibb had a return on equity of 50. 88/$4. As Q1 earnings announcement date approaches, Wall Street is expecting earnings per share of $0. Approval of Orencia in psoriatic arthritis is also a positive. The shares have slowed down in recent weeks, with their price down about -3. The second table on the Estimates page shows analyst Earnings Estimates for the next two quarters, along with estimates for the current and next fiscal year. bmy earnings estimates The biopharmaceutical company reported $0. (RTTNews) - Below are the earnings highlights for Bristol-Myers Squibb Co. Wall Street analysts, on average, had forecast $2. Biotech and pharmaceutical giant Bristol-Myers Squibb Co (NYSE:BMY) this morning posted market-beating Q3 earnings results and announced a restructuring plan it hopes can accelerate the Moving on, Bristol-Myers Squibb Company (BMY) last reported its December 2019 earnings. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. 14 per share for the quarter, up from their prior estimate […]Bristol-Myers Squibb Co (NYSE:BMY) – Equities researchers at William Blair issued their Q1 2020 earnings per share (EPS) estimates for Bristol-Myers Squibb in a research note issued to investors on Thursday, January 24th. for $50 per share in cash and one share of Bristol-Myers Squibb for each share of …Bristol-Myers Squibb Company (BMY) will report its next earnings on Apr 26 BMO. Bristol-Myers Squibb Company | NYSE. 14%) High Target Price Estimate: 70. . The idea is that See Bristol-Myers Squibb Company (BMY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Excluding special items, Bristol said it earned 63 cents a share in the fourth quarter, falling short of the average analyst estimate of 67 cents a share. 15 and non-GAAP EPS in the range of $3. 74. The company’s key oncology products include Opdivo, Sprycel, Yervoy and the recently launched Empliciti. Bristol-Myers: 2Q Earnings Snapshot. Log in or create an account A MarketBeat account allows you to set up a watchlist and receive notifications for stocks you are interested in. 11. . and Capital One Bank (USA), N. BMY will be declaring its Q1 financial results on April 25. 1 percent to $5. Updated stock price target summary. Next Earnings Date: 4/26/2019: Last Bristol-Myers reiterated its adjusted earnings and revenue expectations for 2019. The most Bristol-Myers Squibb Co (BMY) stock quote, charts, historical data, financials. Ford Motor – Ford beat consensus estimates by a penny a share , with adjusted quarterly earnings of 29 cents per share. The consensus earnings estimates for the company have stabilized at US$1. 7 billion in the period,Uk. 5B Home Analyst Estimates Earnings Estimations on Trader’s Radar: Bristol-Myers Squibb Co (NYSE:BMY) Analyst Estimates; BMY) will report earnings per share of $0. Bristol-Myers Squibb (NYSE:BMY) reported Q1 2018 earnings this Morning, coming in at $0. 66-$0. Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $0. Stock - BMY news, historical stock charts, analyst ratings, financials, and today’s Bristol-Myers Squibb Co. View the latest BMY stock price with Barron's. 94 EPS for the quarter, beating analysts’ consensus estimates of $0. 81 in the latest trading session, marking a -0. A month ago, they told us to expect earnings of US$1. 24. Estimates: Analyzed & Visualized. 18 billion and increased 5% from $4. Bristol-Myers Squibb Company's retained earnings for the quarter that ended in Sep. BMY reported 1st quarter earnings on April 26th. What's next for the stock? We take a look at earnings estimates for some clues. 90 for fiscal 2018. 74 per share, for the same period in 2016. sales of blood clot preventer Eliquis gained market share andcsales jumped 37% to $1. Bristol-Myers Squibb (BMY) closed at $52. View a company's historical and forecasted quarterly earnings, estimate trends, and the range of analyst estimates. (NYSE:BMY): Misses EPS estimates by $0. The company provided earnings per share (EPS) guidance of $3. 2019 Bristol-Myers Squibb Announces Time Change for Q4 Earnings Results Conference Call Fundamental company data and analyst estimates New York-based Bristol-Myers Squibb Company BMY is a major producer and distributor of pharmaceuticals and other healthcare related products. The amount the stock market is willing to pay for Bristol-Myers Squibb's earnings, growth and assets is considered below, and whether this is a fair price. (BMY) reported a profit for first quarter that decreased from the same period last year. In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. 31, 24. • The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $1. 65 billion euros, exceeding the 1. 95%. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that BMY has an improving earnings outlook. 21 (from $3. Bristol-Myers Squibb Company (BMY) will report its next earnings on Apr 26 BMO. 52 or 94 cents a year ago. As of Monday, research firm CFRA predicts S&P 500 Q1 earnings will fall 2. (Reuters) - Bristol-Myers Squibb Co on Thursday reported fourth-quarter profit that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its Bristol-Myers Squibb Company 's BMY first-quarter 2018 earnings of 94 cents per share exceeded the Zacks Consensus Estimate of 85 cents and the year-ago quarter earnings of 84 cents. 97 EPS and FY2023 earnings at $7. The company earned $0. 87/$4. Sign Up Log In. 19 billion in Q4 vs. William Blair analyst M. 14%) Bristol-Myers Squibb (NYSE: BMY) releases its next round of earnings this Thursday, Jan. 4%; Homebuilder Earnings Digested – Benzinga. 80 to $3. 2018 was $33,292 Mil . Bristol-Myers Squibb & Celgene Combined Could Generate Earnings of Over $6 Per Share In The Coming Years BMY) announced that it has agreed to acquire Celgene Inc. BMY's fiscal year ends in December. Select an option BMY Bristol-Myers Squibb Co. Investors Quarterly Results . 5x. Growth Estimates BMY IND S&P; Current Qtr (03/2019) 13. 40 Earnings estimates for BMY from thousands of professional and amateur analysts who contribute to a open, crowdsourced estimate data set. Jan 23, 2019 Wall Street analysts see Bristol-Myers Squibb reporting earnings of 85 EPS has stacked up against analyst estimates in the past like this: Find the latest quarterly and yearly earnings forecasts for Bristol-Myers Squibb Company (BMY) at NASDAQ. BMY earnings call for the period ending These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. 25 billion. 90, which is lower than Wall Street’s $2. Pinterest. BMY fell -0. Uk. stock price. 96 per share, according to Thomson Reuters I/B/E/S. 10 and beats on revenues. 87/$4. The analysts’ present consensus range is $0. The greater the percentage of Bristol-Myers Squibb Company BMY is a New York-based major producer and distributor of pharmaceuticals and other healthcare related products. 49. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. The Wall Street estimate would represent a 21. The FDA extends the review period for NKTR-181 NDA by three months. The New York City-based pharmaceuticals giant reported Q4 EPS of $0. Adjusted earnings per share for the quarter was 75 cents, below the consensus forecast of 77 cents. This process utilizes dates of prior earnings reports as an input. An earnings estimate is an analyst's estimate for a company's future quarterly or annual earnings per share (EPS). Revenues rose 5% to $5. A. 7 billion, but missed estimates by (BMY): Total Return Decomposition Total Return EPS Growth Dividend Return Valuation Change. 66% An earnings estimate is an analyst's estimate for a company's future quarterly or annual earnings per share (EPS). The Average Estimate for each time period is the average for the total number of contributing analysts. Bristol-Myers Squibb Co. An earnings estimate is an analyst's estimate for a company's future quarterly or annual earnings per share (EPS). 09 and was a 12% increase from the prior year’s quarter. (BMY) stock collapsed 16% in a Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, January 24th. AMID American Midstream Partners LP. Bristol-Myers released 3rd quarter earnings results on October 25th. The 9 analysts offering 12-month price forecasts for Bristol-Myers Squibb Co Earnings and Sales Forecasts Key to the earnings and sales forecast charts. Revenue and Earnings Estimates: BMY has beat sales estimates in four of the past five quarters and has exceeded earnings estimates in all five previous NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Taisho Pharmaceutical Holdings Co. Earnings estimates for BMY from thousands of professional and amateur analysts who contribute to a open, crowdsourced estimate data set. (BMY) reported earnings 30 days ago. 85 per Share. - including BMY earnings per share estimates and analyst recommendations. Bristol-Myers Squibb (NYSE: BMY) releases its next round of earnings this Thursday, Jan. 08 per share. 69 and low Bristol-Myers' (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. (NYSE: BMY) is …Bristol-Myers Squibb Company 's BMY first-quarter 2018 earnings of 94 cents per share exceeded the Zacks Consensus Estimate of 85 cents and the year-ago quarter earnings of 84 cents. The company boosted its full-year forecast. Bristol-Myers' (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. 78: Agreement is the extent to which all earnings estimates are being revised in the same direction. 20 per share. Earnings guidance. The drugmaker easily beat Wall Street earnings estimates, posting adjusted earnings per share of $0. , Members FDIC. Earnings SummaryEarnings EstimatesEarnings RevisionsEarnings Updated analyst estimates for Bristol-Myers Squibb Co. Author: Zacks Equity ResearchBristol-Myers (BMY) Q4 Earnings Beat Estimates - Yahoohttps://finance. 4 million, slightly missing views. BMY. 10/$4. S. 03 EPS, Q3 2019 earnings at $0. WhatsApp. BMY - Bristol-Myers Squibb Company, stock quotes, stock charts, news, financials, short interest, message boards, insiders, holders, calendars, competitors Earnings: Broadcom beats estimates in Q1, despite massive profit slump March 14, 2019 March 14, 2019 Chipmaking giant Broadcom Inc. (BMY):-Earnings: $1. Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?See stock analyst recommendations for Bristol-Myers Squibb Company (BMY), including history of rankings (upgrades, downgrades). Bristol-Myers Squibb 5. Growth Estimates BMY IND S&P; Current Qtr (03/2019) 0. While the results beat estimates, it also gave a healthy FY2019 outlook that came above the market consensus. 3% year-over-year, with seven out of 11 sectors in the red. 05 to $3. Earnings. 8 million for the quarter ending December 31, 2018. Shares are down 1. (RTTNews) - Bristol-Myers Squibb Co. N. 59The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. 55-3. Earnings vs. estimates are $3. reuters. Bristol-Myers Squibb Co (BMY) main indexes fell slightly on Thursday as support from better-than-feared U. 9 percent to $5. Analyst Recommendations: Each of the last 3 months MY’s analystsPlease note: Dates displayed are estimates of upcoming expected report dates for companies for which Zacks does not have confirmed dates provided by the company. 15B, 3. 07 per share. 83: 32. Total revenues of $5. 23%)The consensus earnings estimates for the company have stabilized at US$1. Adjusted earnings are expected to come in at $4. Talos Energy (TALO) Q4 Earnings and Revenues Beat Estimates CRH Medical (CRHM) Q4 Earnings Match Estimates MongoDB (MDB) Reports Q4 Loss, Tops Revenue Estimates (RTTNews) - Below are the earnings highlights for Bristol-Myers Squibb Co. Actual Analyst Range Research & Ratings Bristol-Myers Squibb Co. BMY will report Q1 earnings on 04/25/2019 . 33 billion in the same period last year. Analysts are forecasting revenue to climb 11. Quarterly Results . 21 (from $3. Earnings, adjusted for non-recurring costs, came to $1. 94 in earnings …Bristol-Myers Squibb Co (NYSE:BMY) stock was down today following the release of its earnings report for the third quarter of 2017. Net profit dropped to $1. ( GOOGL ) is the highlight Monday. even if our estimates change, whether as a result of new information, future events or otherwise. com. Bristol-Myers Earnings Miss, Outlook Cut BMY cut its earnings guidance for 2017. BMY Earnings Dates Upcoming and Historical A table for both the upcoming quarterly earnings releases and historical releases for BMY, if available. 81% for fiscal 2018, fiscal 2019, and fiscal 2020, respectively. The biopharmaceutical company posted revenue of $5. Dec 2019, 23. even if our estimates change Bristol-Myers Squibb Co (NYSE:BMY) issued its quarterly earnings results on Thursday, January, 24th. 30-$4. 94 compared to the consensus analysts' estimate of $0. The most estimates are $3. Including historical share prices, analysis, earnings, cash flow and market valuation for Bristol-Myers Squibb Co. 18 ahead The company earned $1. The company had revenue of $5. 94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0. Estimates. 94 per share in Q1, which beat estimates by The company earned $0. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. Bristol-Myers Squibb (BMY) reports earnings on 4/25/2019. 47 billion, or $0. 09 per share, $0. Find the latest quarterly and yearly earnings forecasts for Bristol-Myers Squibb Company (BMY) at NASDAQ. 11 (-0. 97 billion versus the consensus estimate of $5. 95 per share. ² Remember, a company is not permitted to discuss interim earnings with select individuals; earnings reports must be disseminated publicly to level the playing field for all investors. Estimates; Estimate Type Current Quarter ¹ Fiscal Year End for Bristol-Myers Squibb Co falls in the month of December. But this is just one piece of the puzzle for value investors. 04 for the current quarter based on the opinion of 8 analysts, relating to high earnings per share estimates of $1. But the list expands to 36 names if we look for stocks that have gotten 20% cheaper relative to forward earnings estimates. Earnings estimates for Q1 continue to look pretty soft. S&P 500 component Bristol-Myers Squibb Company reported its results for the fourth quarter. Analysts are expecting average earnings estimates of $1. 94. Analysts 2023-12-31 2022-12-31 2021-12-31 4. 63% P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Analysts are expecting average earnings estimates of $1. 5B For example, these estimates may guide investors in determining an appropriate price for a company’s stock. 75 per share a year ago. 94 per share, beating Wall Street’s estimates of $0. NYSE:BMY Future Estimates Data; Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. This compares to earnings of $0. 4% to $5. BMY surpassed analysts’ consensus estimate for revenue Celgene Q4 2018 Earnings Infographic. com/news/bristol-myers-bmy-q4-earningsFeb 05, 2018 · Bristol-Myers Squibb Company BMY is a New York-based major producer and distributor of pharmaceuticals and other healthcare related products. Actual Analyst Range Consensus. PE (price-to-earnings) multiples represent what one share of a company can buy for an equity investor. 97 billion for the quarter, compared to analyst estimates of $5. Nevertheless, that result is well-below the Jan 04, 2019 · Bristol-Myers Squibb (NYSE:BMY) announced that it has agreed to acquire Celgene Inc. 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. com. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. Bristol-Myers Squibb Company BMY is a New York-based major producer and distributor of pharmaceuticals and other healthcare related products. 91 per share. The company's earnings came in at $1. 98 billion but increased 10% from $5. DOW JONES, A NEWS CORP COMPANY. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 87 cents per share. 06 per share. The bad news for BMY stock starts with earnings per share of 75 Colgate-Palmolive bested Q4 earnings and revenue estimates, boosting beaten-down shares. Bristol-Myers Squibb (BMY) beat Wall Street estimates for earnings per share and revenues during 4Q17. However management expects EPS to decline in 2019, despite projected organic sales growth. ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb (BMY) Announces Quarterly Earnings Results, Beats Estimates By $0. (BMY) on Thursday reported third-quarter earnings of $1. Bristol-Myers Squibb Co (BMY:NYQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. First-quarter earnings before interest and taxes rose 7. The greater the percentage of Bristol-Myers Squibb Company (BMY) [[ item. 20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4. The biopharmaceutical company reported $0. 9 per share. Bristol-Myers Squibb Company (BMY) NYSE - NYSE Delayed Price. See stock analyst recommendations for Bristol-Myers Squibb Company (BMY), including history of rankings (upgrades, downgrades). Add to watchlist. 65 4. Toggle navigation. (AVGO) announced its first-quarter 2019 earnings on March 14, after the… Analysts are expecting average earnings estimates of $1. Bristol-Myers (BMY) reported earnings 30 days ago. The report will be for the fiscal Quarter ending Mar 2019. Bristol-Myers (BMY) Stock Slides Despite Q2 Earnings, Revenue Beat Bristol-Myers (BMY) reported 2016 second-quarter financial results that beat estimates before the market open. 94 earnings per share for the quarter, topping analysts' consensus estimates of $0. Signup/Login BMY – Beats EOS estimates by $0. Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, January 24th. New York-based Bristol-Myers Squibb Company BMY is a major producer and distributor of pharmaceuticals and other healthcare related products. 14 in EPS and $24. estimates are $3. Sales increased 1% from the year-ago quarter to $20. View BMY's earnings history, next earnings date and consensus earnings estimates from top-rated Wall Street analysts at MarketBeat. 18). 04 per share. 49, 23. BMY fell -3. Earnings Estimates are available only for US equities. The drugmaker easily beat Wall Street earnings estimates, posting adjusted earnings per share of $0. (Mar 2019) Next Qtr. Key risks to our BMY call include better or worse-than-expected adoption of Opdivo, better or worse-than-expected pipeline data, and the potential for BMY to be an acquisition target given its discounted multiple compared to peers. View comprehensive quarterly earnings reports and learn more about investing in Bristol-Myers Squibb. Dec 2020, 25. JetBlue ( JBLU ) said it earned $155 million in net income in the fourth quarter of 2018, exceeding expectations of $131. Rachel GrafThe enterprise software maker's adjusted fourth-quarter earnings rose 120% to 77 cents a share, topping estimates of 64 cents. 84 per share, in the first quarter, compared to $1. Here's Benzinga's essential guide to Bristol-Myers Squibb's Q4 earnings report. Forward PE. 28. Earnings: 94 cents per share, BMY---Subscribe to CNBC PRO. Bristol-Myers Squibb (NYSE:BMY) issued its quarterly earnings results on Thursday, January 24th. Bristol-Myers Squibb Co. Compare historical estimates against actual numbers and past tendency to suprise to understand a company's chances of outperforming its expectations. ly/2El7g60Estimates: Analyzed & Visualized. The bad news for BMY stock starts with earnings per share of 75 Bristol-Myers Squibb Co (NYSE:BMY) – Research analysts at William Blair lowered their FY2019 earnings estimates for Bristol-Myers Squibb in a report released on Tuesday, February 19th. 85. Summary; Earnings; Dividends; StockTalk; Key Data; Earnings Summary Earnings Estimates Earnings Revisions …BMY – analyst ratings, historical stock prices, earnings estimates & actuals for Bristol-Myers Squibb Co. 66% Bristol-Myers Squibb (NYSE: BMY) releases its next round of earnings this Thursday, Jan. Shares are up 5. Adjusted earnings were $1. During the past three months, the average estimate has moved down from 56 cents. 97 Research & Ratings Bristol-Myers Squibb Co. 69 and low forecast is $0. 17/$4. 09, Bloomberg Earnings reports. Bristol-Myers Squibb issued an update on its FY18 earnings guidance on Thursday, July, 26th. 08 for the current quarter based on the opinion of 7 analysts, relating to high earnings per share estimates of $1. Colgate-Palmolive bested Q4 earnings and revenue estimates, boosting beaten-down shares. Future earnings estimates are arguably the most important input when attempting Quarterly Consensus Estimates and Ranges BMY's fiscal year ends in December Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Bristol-Myers Squibb (NYSE:BMY) reported Q1 2018 earnings this Morning, coming in at $0. BMY Per-Share Earnings, Actuals and Estimates. 55 from $0. 03 worse than the Wall Street consensus estimate of $0. 20 EPS. Third-Quarter Earnings: Up 15 percent (yoy) to $0. com provides latest share Market news, stock market advice, world market reports, UK Stock Exchange movements for BMY. 95% and a return on equity of 50. 1 per share three months ago. Beyond oncology, the …Bristol-Myers Squibb Co (NYSE:BMY) – Equities researchers at William Blair issued their Q1 2020 earnings per share (EPS) estimates for Bristol-Myers Squibb in a research note issued to investors on Thursday, January 24th. 65 for the period, compared to the Thomson Reuters consensus estimate of $3. 05 to $3. 06% in the past three months. 17 per share, also exceeding consensus estimates of $1. For the current quarter the company has highest EPS estimates of $0. 45 billion-euro average of three analyst estimates compiled by Bloomberg. 18 ahead of estimates and a 45% increase from the previous year. (Taisho) has offered to purchase Bristol-Myers Squibb’s UPSA NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Taisho Pharmaceutical Holdings Co. Some might point to the strength that Bristol-Myers Squibb demonstrated in Q4 as a reason that the company doesn't need to make a major acquisition. 67 in their quarterly report and it is expected to announce the company’s results on 7/28/2016 BMO. 94/Share in the last quarter where the …William Blair Equities Analysts Reduce Earnings Estimates for Bristol-Myers Squibb Co (BMY) Posted by Joseph McCarthy on Feb 24th, 2019 // No Comments Bristol-Myers Squibb Co (NYSE:BMY) – Equities research analysts at William Blair dropped their FY2019 EPS estimates for Bristol-Myers Squibb in a report issued on Tuesday, February 19th. 45 billion recorded in the year-ago period. 03. See stock analyst recommendations for Bristol-Myers Squibb Company (BMY), including history of rankings (upgrades, downgrades). This change lagged the S&P 500's daily loss of 0. Quarterly; Annual; BMY will report Q1 earnings on 04/25/2019 . The Earnings Whisper ® number was $0. The company provided earnings per share guidance of $4. Bristol-Myers Squibb Company (BMY) will report its next earnings on 27-Apr-17. 11. Bristol-Myers Squibb Company Earnings Estimates. 67/share. 71B in the next fiscal quarter, while earnings are seen soaring by nearly 10. Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?Apple Inc. 00 to $1. The …Bristol-Myers Squibb Company BMY is a New York-based major producer and distributor of pharmaceuticals and other healthcare related products. Strong sales of BMY’s Opdivo and Empliciti cancer drugs couldn’t offset poor performance from a host of others, including skin cancer treatment Yervoy, Eliquis deep vein thrombosis pills and rheumatoid arthritis drug Orencia. Updated analyst estimates for Bristol-Myers Squibb Co. 03% and a net margin of 21. View the latest BMY stock price with Barron's. 37% (NYSE:BMY). The company’s key oncology products include Opdivo BMY – analyst ratings, historical stock prices, earnings estimates & actuals for Bristol-Myers Squibb Co. Get Bristol-Myers Squibb alerts: Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. 34% move from the prior day. 94 per share in Q1, which beat estimates by $0. Phipps now forecasts that the biopharmaceutical company will post earnings …View a company's historical and forecasted quarterly earnings, estimate trends, and the range of analyst estimates. -$2. 77B in the next fiscal quarter, while earnings are seen soaring by nearly 14. These estimates don’t include the impact of the pending Celgene Bristol-Myers Squibb Co. Bristol-Myers Squibb Co (NYSE:BMY) – William Blair upped their Q1 2019 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a report issued on Thursday, March 14th. Earnings Whispers is the only provider of real, professional whisper numbers for professional traders and investors - the most reliable earnings expectation availabe - based on superior fundamental research that is combined with investor sentiment data, quantitative studies, and technical analysis to create a valuable indicator for favorable Bristol-Myers Squibb Co (NYSE:BMY) announced its quarterly earnings results on Thursday, January, 24th. 06 per share. (NYSE: BMY) reported its most recent quarterly results before the markets opened on Thursday, the company said that it had $0. 93 billion recorded in the year-ago period. Currency in USD. 09 better than the analyst estimate of $0. 95%, and 9. 52 or 94 cents a year ago. , Ltd. (NASDAQ:AAPL), Bristol-Myers Squibb Company (NYSE:BMY) – Yields In Focus Again As 10-Year Falls Below 2. The …Banking and lending products and services are offered by Capital One, N. 88/$4. 25 higher than the prior guidance. Bristol-Myers Squibb (NYSE:BMY) updated its FY19 earnings guidance on Thursday. …Only two weeks after announcing its massive acquisition of Celgene Corporation, drug-maker Bristol-Myers Squibb (BMY) is all set to report fourth-quarter results on Thursday, January 24. 09 per share while three months ago their EPS consensus estimate was US$1. Talos Energy (TALO) Q4 Earnings and Revenues Beat Estimates CRH Medical (CRHM) Q4 Earnings Match Estimates Micron Poised to Report Great Results, but the Outlook Matters More The drugmaker easily beat Wall Street earnings estimates, posting adjusted earnings per share of $0. More Bristol-Myers Squibb Company ’s BMY first-quarter 2018 earnings of 94 cents per share exceeded the Zacks Consensus Estimate of 85 cents Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. 94/Share in the last quarter where the estimated EPS by analysts was $0. 63, which was $0. Bristol-Myers Squibb Company (NYSE:BMY) Retained Earnings: $33,292 Mil (As of Sep. 5 billion for 4Q17. Earnings Estimate Current Qtr. 55B and $4. 94 per share, beating Wall Street’s estimates of $0. Find real-time BMY - Bristol-Myers Squibb Co stock quotes, company profile, news and forecasts from CNN Business. 95 billion. March 27, 2019. BMY $48. Beyond oncology, the …Bristol-Myers Squibb (NYSE:BMY) updated its FY19 earnings guidance on Thursday. (actuals, guidance) provided by Benzinga, Wall Street estimates provided by Zacks, economic provided by Trading Economics, earnings report dates provided by Wall Street Horizon, market data is at least View comprehensive quarterly earnings reports and learn more about investing in Bristol-Myers Squibb. 10-4. Below are the earnings highlights for Bristol-Myers Squibb Co. Updated analyst estimates for Bristol-Myers Squibb Co. Peer group for Bristol-Myers based on S-4 peers; peers for Pfizer and Merck includes AZN, BMY, GSK, JNJ, LLY, MRK, NOVN, PFE, ROG, SAN; Bristol-Myers, Merck and Pfizer Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, January 24th. Our current price estimate of $56 for Bristol-Myers Squibb is based on expected adjusted earnings of $3. 94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0. 85B, 3. 07 (+0. Projected earnings dates are based on past patterns. 09. Bristol-Myers Squibb (BMY) expects to report GAAP EPS in the range of $3. Revenue for the quarter came in at $5. The company earned $1. This company's ROIC during its last fiscal year ranks in the Top Quintile. Google+. 97 billion marginally lagged the Zacks Consensus Estimate of $5. The consensus earnings estimates for the company have stabilized at US$1. Twitter. 94, however Bristol-Myers Squibb Company (NYSE:BMY) reported $0. Analysts are revising their future earnings and sales projections upwards due to MY’s strong performance. Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, January 24th. SunTrust Banks analyst J. 94 earnings per share for the same quarter last year. 75. Bristol-Myers Squibb (NYSE:BMY) reported Q4 2018 earnings this Morning, coming in at $0. These estimates don’t include the impact of the pending Celgene View the latest BMY stock price with Barron's. 41. Bristol Myers-Squibb (BMY) raised its full year earnings forecast but near term sales disappointed. products from cardio JV in Merck total; figures for Bristol-Myers’ acquisition of Celgene based on Evaluate Pharma 2024 estimates 3. 2/14/2019. Home. 5B or 91 cents a share compared to $1. 75 per share Detailed Earnings Estimates. Compare historical estimates against actual numbers and past tendency to suprise to understand a company's chances of outperforming its expectations. Estimates » More Financials. 19 billion in Q4 vs. Bristol-Myers Earnings estimates for BMY from thousands of professional and amateur analysts who contribute to a open, crowdsourced estimate data set. The firm had revenue of $5. 96 0. 18 and low estimates of $0. Earnings for Bristol-Myers Squibb Company $ 49. 72% in the past three months. 77B in the next fiscal quarter, while earnings are …Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates Zacks 11:25AM Activist investor Starboard Value says it will oppose Bristol-Myers' $74 billion deal for Celgene cnbcApple Inc. 20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4. Bristol-Myers’ fourth-quarter 2018 earnings of 94 cents per share exceeded the Zacks Consensus Estimate of 85 cents and the year-ago quarter earnings of 68 cents. “During the first quarter we delivered strong sales and earnings growth, achieved important regulatory milestones for Opdivo in the U. (BMY): -Earnings: $1. 66. -EPS: $0. 18 ahead of estimates and a 45% increase from the previous year. In contrast, MY’s other metrics were inflated due to their transition which required cost cutting measures. ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb (BMY) Announces Quarterly Earnings Results, Beats Estimates By $0. Revenue rose 30% to $715. 1 percent to $5. Bristol-Myers Squibb Company BMY, one of the A consensus estimate is a figure based on the combined estimates of analysts covering a public company. 27. for $50 per share in cash and one share of Bristol-Myers Squibb for each share of Celgene, which translates The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that BMY has an improving earnings outlook. 4 billion while earnings per share rose 13. What is an 'Earnings Estimate'. 96 up $0. 10-4. 70 to $2. 00: Low Target Price Estimate: 52. S&P 500 Earnings Ahead of Estimates but 2019 Profit Growth Set to Slow Sharply Google parent Alphabet Inc. Phipps now forecasts that the biopharmaceutical company will post earnings of $1. include a joint proxy statement of Bristol-Myers Squibb and Celgene that also constitutes a prospectus of Bristol-Myers Squibb, and a definitive joint proxy statement/prospectus will be mailed to stockholders of Bristol-Myers Squibb and Celgene. ESTIMATES Fundamental company data (actuals, guidance) provided by Benzinga, Wall Street estimates provided by Zacks, economic indicators The consensus earnings estimates for the company have stabilized at US$1. BMY performed exceptionally in this metric with a PEG ratio of 2. (NYSE:BMY): Beats EOS estimates by $0. 33 billion in the same period last year. As of Monday, research firm CFRA predicts S&P 500 Q1 Bristol-Myers released 3rd quarter earnings results on October 25th. Six of these are highlighted below. Banking and lending products and services are offered by Capital One, N. 09 See stock analyst recommendations for Bristol-Myers Squibb Company (BMY), including history of rankings (upgrades, downgrades). Third Point holds Celgene stock, in bet Bristol-Myers deal will close: source Third Point holds Celgene stock, in bet View the latest BMY stock price with Barron's. Signup/Login Search. Barchart uses Zack's earnings estimates, generated by their market analysts and used to project profitability. Bristol-Myers Squibb Co News. 97 EPS. A look at Allergan’s Q3 2018 estimates . The company projects earnings in the range of $4. Follow up to five stocks for free. 03 The latest earning call transcripts on Bristol-Myers Squibb Company (BMY) stock. 2 billion, or $0. 7 times forward earnings estimates. 85 Bristol-Myers Squibb (NYSE:BMY) announced that it has agreed to acquire Celgene Inc. …View BMY's earnings history, next earnings date and consensus earnings estimates from top-rated Wall Street analysts at MarketBeat. 67 in their quarterly report and it is expected to announce the company’s results on 7/28/2016 BMO. 9 billion. Earnings Surprises, Estimates and Recommendations History. Bristol-Myers Squibb Co Earnings: 10 Things to Know About Q4 BMY beat Q4 EPS and revenue estimates By William White, InvestorPlace Writer http://bit. (EPS) for the quarter, topping analysts’ consensus estimates of $0. When Bristol-Myers Squibb Co. BMY earnings call for the period ending These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. Latest Breaking news and Headlines on Bristol-Myers Squibb Company (BMY) stock from Seeking Options Bets Paint Dire Outlook For Celgene/Bristol Deal. Future earnings estimates are arguably the most important input when attempting Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, January 24th. 53%. Earnings Summary Earnings Estimates Earnings Revisions Earnings Surprise Transcripts Analyst Ratings. Bristol-Myers Squibb Co early Thursday posted mixed fourth quarter earnins reuslts and lowered its 2017 outlook, amid fears of regulators capping drug prices. The company provided earnings per share (EPS) guidance of $4. Revenue also beat estimates amid increased production of the Model 3. lastPrice ]] [[ item. 85. Find the latest quarterly and yearly earnings forecasts for Bristol-Myers Squibb Company (BMY) at NASDAQ. We expect the company to post steady top line and bottom line growth led by its oncology and cardiovascular The consensus earnings estimate was $0. 45B, 24. Access present, future and past earnings, sales and EBITDA estimates for a universe of 3000+ stocks. We take a look at earnings estimates for some clues. Fourth Quarter Earnings Sneak Peek. 94 EPS for the quarter, topping analysts’ consensus estimates of $0. 19: Agreement is the extent to which all earnings estimates are being revised in the same direction. Wall St. Revenue grew 8. 29B, 10. ),Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene The drugmaker easily beat Wall Street earnings estimates, posting adjusted earnings per share of $0. Bristol-Myers Squibb Co discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. Allergan (), a leading pharmaceutical company, is set to release its third quarter of 2018 earnings on October 30. 09 per share, rising 45% to beat the analyst average of 91 cents. 80 to $3. Bristol Myers-Squibb (BMY) raised its full year earnings forecast but near term sales disappointed. 18 and low estimates of $1. 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks Equity Research. Boris now expects that the biopharmaceutical company will post earnings of $4. 10 to $4. In the third quarter, Bristol reported adjusted earnings of The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. The company also said it expects 2019 earnings of $1. 48 Consensus Estimates pegged eps at $0. N. 04 for the current quarter based on the opinion of 8 analysts, relating to high earnings per share estimates of $1. Detailed Earnings Estimates. Earnings estimates provided by Zacks. 07 per share while three months ago their EPS consensus estimate was US$1. 94 EPS for the quarter, beating the consensus estimate of $0. 94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0. 63/Share in the last quarter where the estimated EPS by analysts was $0. bmy earnings estimatesFind the latest quarterly and yearly earnings forecasts for Bristol-Myers Squibb Company (BMY) at NASDAQ. Analysts are forecasting revenue to climb 9. Bloomsbury Publishing's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average. Investors disappointed with Opdivo and uncertain about the Celgene acquisition have driven Bristol-Myers Squibb stock down to just 11. Fiscal Period Ending, Revenue Estimate, FWD Price/Sales, Low, High, # of Analysts. The market consensus range for revenue is between $4. 09 per share, $0. 03 on revenues of $3. Bristol-Myers Squibb Co (NYSE:BMY) – Research analysts at William Blair lowered their FY2019 earnings estimates for Bristol-Myers Squibb in a report released on Tuesday, February 19th. Investment advisory services are provided by Capital One Advisors, LLC, an SEC-registered investment advisor. Bristol-Myers These documents are available from the Securities and Exchange Commission, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. Let’s take a look at some of BMY’s valuation multiples. Early movers: BP, F, AAPL, BMY, COH, PFE & more BP reported quarterly earnings of $2. 18. 09 and was a 12% increase from the prior year’s quarter. Narrative Science Partner Opinions expressed by Forbes Contributors are their own. ly/2El7g60Bristol-Myers Squibb Co (NYSE:BMY) stock was down today following the release of its earnings report for the third quarter of 2017. 07 (0. When Bristol-Myers Squibb Co. Revenue and Earnings Estimates: BMY has beat sales estimates in four of the past five quarters and has exceeded earnings estimates in all five previous quarters. Please note: Dates displayed are estimates of upcoming expected report dates for companies for which Zacks does not have confirmed dates provided by the company. 2019 Bristol-Myers Squibb Announces Time Change for Q4 Earnings Results Conference Call Fundamental company data and analyst estimates View the latest BMY stock price with Barron's. 01 per share. 33 percent increase in the company's earnings. Bristol-Myers Squibb had a net margin of 21. Investment products are offered by Capital One Investing, LLC, a registered broker-dealer and Member FINRA/SIPC. The company also announced that it has acquired IPierian. 99 . 01, however Bristol-Myers Squibb Company (NYSE:BMY) reported $0. Bristol-Myers Squibb Company BMY is a New York-based major producer and distributor of pharmaceuticals and other healthcare related products. 85 per share. Generally, analysts give a consensus for a company's earnings per share (EPS) and revenue Here’s your Earnings Cheat Sheet for Bristol Meyers Squibb (BMY). Adjusted earnings grew 20% in the quarter, while total revenue jumped 16%. Facebook. Bristol-Myers Squibb had a return on equity […] Bristol-Myers Squibb (NYSE:BMY) released its quarterly earnings results on Thursday. 09 per share, beating the Zacks Consensus Estimate of $0. (BMY) high and low estimates, analyst averages and year-over-year earnings growth rates for Bristol-Myers Squibb (BMY) reports earnings on 4/25/2019. 5B or 91 cents a share compared to $1. 89 percent to $1. 94, $0. (Jun 2019) Bristol-Myers Squibb Co early Thursday posted much better than expected first quarter earnings results and lifted its full-year outlook, as sales of several of its new drugs begin to skyrocket. The latest earning call transcripts on Bristol-Myers Squibb Company (BMY) stock. Why the Bristol-Myers Incredible Earnings Beat Is Getting Grounded. Bristol-Myers […] Bristol-Myers Squibb (NYSE:BMY) released its quarterly earnings results on Thursday, January 24th. 94 earnings per share for the same quarter last year. 94 earnings per share for the quarter, beating analysts’ consensus estimates of $0. They were forecasting US$1. 94 per share in Q1, which beat estimates by The company earned $0. 2% to $1. 85 for Bristol-Myers Squibb on an adjusted basis. Bristol-Myers Squibb is a global company that develops, manufactures, and sells pharmaceutical products. (BMY) stock collapsed 16% in a Before Tuesday’s opening bell, Bristol-Myers Squibb Co (BMY) reported first higher first quarter earnings, which came in above analysts’ estimates. Bristol-Myers Squibb expects to report GAAP EPS in the range of $3. 36 per share, above analyst estimates for $4. 19 billion were slightly higher than the Zacks Consensus Estimate of $5. 66 per share for the year, up from their previous forecast of $4. 18. Earnings Expectations: The average estimate of analysts is for profit of 55 cents per share, a rise of 17% from the company’s actual earnings for the same quarter a year ago. The Zacks Consensus Estimate for earnings is pegged at $4. 18 and low estimates of $0. Inside J&J & Bristol-Myers’ Q4 Earnings: J&J beat estimates for both earnings and sales in the fourth quarter of 2018. Earnings announcement* for BMY: Apr 25, 2019 Bristol-Myers Squibb Company is expected* to report earnings on 04/25/2019 before market open. Change company Symbol lookup. 15 per share. 64 percent to $1. 94 earnings per share for the quarter, beating the consensus estimate of $0. Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended. The latest earning call transcripts on Bristol-Myers Squibb Company (BMY) stock. 94 EPS for the quarter, topping the consensus estimate of $0. 17/$4. Research & Ratings Bristol-Myers Squibb Co. 16 per share on revenue of $376. Eliquis and Opdivo continue to record solid sales. 09 EPS” was first reported by Markets Daily and is owned by of Markets Daily. Earnings for Bristol-Myers Squibb (BMY) Expected to Fall. 03 Latest Breaking news and Headlines on Bristol-Myers Squibb Company (BMY) stock from Seeking Options Bets Paint Dire Outlook For Celgene/Bristol Deal. Note that the earnings and revenue estimates may change ahead of the formal reports, and some companies may reschedule reporting dates as well. Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. Estimates » More Financials. Future earnings estimates are arguably the most important input when attempting to value a firm. Earnings date: while sales miss estimates in the fourth quarter of 2018. 20 for the period, compared to the Thomson Reuters consensus estimate of $4. The search giant reports earnings after the closing bell. Earnings announcement* for BMY: Apr 25, 2019 Bristol-Myers Squibb Company is expected* to report earnings on 04/25/2019 before market open. A month ago, analyst EPS consensus estimated earnings of US$1. 00: 23. The results topped Wall Street expectations. Bristol-Myers (BMY) beats earnings estimates in the fourth quarter but misses sales expectation by a slight margin. 04%, while the tech-heavy Nasdaq lost 0. com provides latest share Market news, stock market advice, world market reports, UK Stock Exchange movements for BMY. 8 for EPS. An overview of specified items is discussed under …Bristol-Myers, with a market value of $78 billion, trades for 11 times projected 2019 earnings of $4. By placing estimates on the earnings of a firm for certain periods (quarterly, annually, etc. Bristol-Myers Squibb (BMY) reports earnings on 4/25/2019. 4 billion, or $0. BMY’s Earnings in Brief BMY posted Q1 earnings of $937 million, or 56 cents per share BMY will be declaring its Q1 financial results on April 25. com for BMY. 18). 07 per share while three months ago their EPS consensus estimate was US$1. Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades. Rachel Graf(RTTNews) - Below are the earnings highlights for Bristol-Myers Squibb Co. Bristol-Myers Squibb (NYSE:BMY) is scheduled to announce its Q4 earnings on January 24. 94, however Bristol-Myers Squibb Company (NYSE:BMY) reported $0. 94 compared to the BMY earnings call for the period ending These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. BMY reported revenues of $5. 05 down $0. Bristol-Myers Squibb Co (NYSE:BMY) – Equities researchers at William Blair raised their Q1 2019 earnings estimates for shares of Bristol-Myers Squibb in a research report issued to clients and investors on Thursday, March 14th. 85 by $0. 94 in earnings per share (EPS) and $5. GDP data was countered by concerns about earnings and Earnings vs. 2018) Retained earnings is the accumulated portion of net income that is not distributed to shareholders. It now expects EPS for the year of $2. Bristol-Myers Squibb Co (BMY:NYQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Bristol-Myers Squibb (BMY) came out with quarterly earnings of $1. 88 billion. 2% since reporting last quarter. Bristol-Myers Squibb also updated its FY 2019 guidance to $4. reuters. potential. 97 billion during the quarter, compared to analyst estimates of $5. Earnings estimate Current qtr. Net profit dropped to $1. Earnings estimates for Q1 continue to look pretty soft. march 23 (reuters) - bristol-myers squibb co ::mercy investment services - at bristol-myers shareholders’ meeting, shareholders will have chance to vote on proposal sponsored by multiple Bristol-Myers slashes its 2017 outlook. Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, January 24th. 03%. Bristol-Myers Squibb (NYSE:BMY) released its quarterly earnings results on Thursday. 59Bristol-Myers Squibb (BMY) expects to report GAAP EPS in the range of $3. BMY Future Estimates Data Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. 10/$4. Third Point holds Celgene stock, in Bristol beat analysts' earnings estimates but fell short of revenue expectations. Bristol-Myers Squibb Co early Thursday posted much better than expected first quarter earnings results and lifted its full-year outlook, as sales of several of its new drugs begin to skyrocket. 12 a share and for only eight times estimated 2020 profits of about $6. For brief highlights, it performed well in that quarter, with earnings up 38% year-over-year at $0. Beats on revenues. Third Point holds Celgene stock, in bet Bristol-Myers deal will close: source Third Point holds Celgene stock, in bet Bristol-Myers Earnings Beats. Phipps now forecasts that the biopharmaceutical company will post earnings …In the same quarter last year, Bristol-Myers Squibb reported EPS of 75 cents on revenue of $5. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2019 earnings at $1. yahoo. 2 billion in revenue for the year. 92B, with an average of $4. Source: New Constructs, LLC Bristol Myers Squibb Co (BMY) Figure 4: Return on Invested Capital vs Weighted Average Cost of Capital VALUATION REPORT ® Bristol-Myers Squibb Company has a Earnings Yield (Joel Greenblatt) %: 7. According to consensus agreement of 21 analysts Bristol-Myers Squibb Co (NYSE:BMY) will report earnings per share of $0. The company expects revenue per available seat mile to rise 4% to 5% in the first quarter of 2019. 14. Jan 04, 2019 · This is much higher than the current earnings estimate of $3. The company surprised analysts by 11 who were expecting $0. 7 percent to 2. 25%. 2B which was 15 below consensus’s estimates. Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?William Blair Equities Analysts Reduce Earnings Estimates for Bristol-Myers Squibb Co (BMY) Posted by Joseph McCarthy on Feb 24th, 2019 // No Comments Bristol-Myers Squibb Co (NYSE:BMY) – Equities research analysts at William Blair dropped their FY2019 EPS estimates for Bristol-Myers Squibb in a report issued on Tuesday, February 19th. Actual Analyst Range Find information on BMY stocks for stockholders, potential investors & financial analysts. 94 per share in Q1, which beat estimates by $0. 4% since reporting last quarter. 62. As of Monday, research firm CFRA predicts S&P 500 Q1 BMY reported 1st quarter earnings on April 26th. 00: Mean Target Price Estimate Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, January 24th. Wall Street analysts estimate EPS of $4. What's next for the stock? We take a look at earnings Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, January 24th. Jan 24, 2019 · Bristol-Myers (BMY) beats earnings estimates in the fourth quarter but misses sales expectation by a slight margin. 1. Heading into today, shares of the biopharmaceutical BMY will be showing off its Q1 earnings on April 25. 239 billion. Bristol-Myers Squibb Co Earnings: 10 Things to Know About Q4 BMY beat Q4 EPS and revenue estimates By William White, InvestorPlace Writer http://bit. 94 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0. and Europe and presented important new The chart above shows the comparison between analysts’ estimates and actual EPS over the last few quarters. 90 for fiscal 2018, $0. BMY $49. …Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades. 85 per share and an earnings multiple of 14. Bristol-Myers Earnings Beats. 20 per share; in-line with the consensus estimate of $1. Bristol-Myers Squibb Company Earnings Yield (Joel Greenblatt) % description, competitive comparison data, historical data and more. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. BMY. 85 by $0. 94 compared to the consensus analysts' estimate of $0. Mar 26, 2019 · Updated analyst estimates for Bristol-Myers Squibb Co. Jan 25, 2019 Earnings estimates for Bristol-Myers Squibb Co. Earnings Whispers is the only provider of real, professional whisper numbers for professional traders and investors - the most reliable earnings expectation availabe - based on superior fundamental research that is combined with investor sentiment data, quantitative studies, and technical analysis to create a valuable indicator for favorable Earnings estimates for BMY from thousands of professional and amateur analysts who contribute to a open, crowdsourced estimate data set. Analysts expect the company to post earnings of 85 cents per share on …Bristol-Myers Squibb Co. 53 this quarter. 97 estimate. 2B which was 15 below consensus’s estimates. 74B. 94 earnings per share for the quarter, topping analysts' consensus estimates of $0. Elsewhere, the Dow gained 0. and should not be relied upon as representing our estimates as of any Connect to the most current information on stocks and bonds on Reuters. News Corp is a network of leading companies in the worlds of diversified …Growth Estimates BMY IND S&P; Current Qtr (03/2019) 13